GoodRx Achieves HITRUST i1 Certification to Manage Data Protection and Mitigate Cybersecurity Threats

HITRUST certification validates that GoodRx is operating leading security practices to protect sensitive information

GoodRx Achieves HITRUST i1 Certification to Manage Data Protection and Mitigate Cybersecurity Threats

GoodRx (Nasdaq: GDRX), the leading medication savings platform in the U.S., today announced its drug savings platform residing with Amazon Web Services (AWS) has earned certified status for 2025 by HITRUST for information security. This milestone underscores GoodRx’s dedication to safeguarding data and maintaining specific standards of cybersecurity in healthcare.

HITRUST i1 Certification demonstrates that GoodRx’s drug savings platform is leveraging a set of curated controls to protect against current and emerging threats. The HITRUST i1 Validated Assessment and Certification helps organizations address cybersecurity challenges and remain cyber resilient over time. The company’s adherence to the i1 certification is assessed by third-party auditors on an annual basis.

“GoodRx’s HITRUST i1 Certification is further evidence that they are committed to best practices for information risk management and cybersecurity,” said Jeremy Huval, Chief Innovation Officer at HITRUST. “HITRUST is continually innovating to find new and creative approaches to address information security challenges.”

The HITRUST i1 Certification for GoodRx’s medication savings platform reflects a strong commitment to data security and risk management. Covering AWS data centers in California, Ohio, Oregon, and Virginia, this certification validates GoodRx’s adherence to regulatory standards and strengthens trust among consumers, healthcare providers, and industry partners. By achieving this milestone, GoodRx reinforces its leadership in healthcare data protection and gains a competitive edge in delivering reliable savings solutions.

“HITRUST i1 Certification is an important validation of the security and compliance measures we prioritize at GoodRx,” said Nitin Shingate, Chief Technology Officer at GoodRx. “Protecting data is fundamental to how we operate, and this certification provides an additional proof point of our commitment to cybersecurity and data protection.”

About GoodRx

GoodRx is the leading platform for medication savings in the U.S., used by nearly 30 million consumers and over one million healthcare professionals annually. Uniquely situated at the center of the healthcare ecosystem, GoodRx connects consumers, healthcare professionals, payers, PBMs, pharma manufacturers, and retail pharmacies to make saving on medications easier. By reducing friction and inefficiencies, GoodRx helps consumers save time and money when filling prescriptions so they can get the care they deserve. Since 2011, GoodRx has helped Americans save over $75 billion on the cost of their medications.

?GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission (the “SEC”) and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release.

GoodRx Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding anticipated consumer savings, convenience and accessibility; the expected benefits and value of our partnership with HITRUST and other offerings; and our plans, expectations and objectives. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to achieve broad market education and change consumer purchasing habits; changes in medication pricing and pricing structures; our reliance on a limited number of industry participants; and the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023, and our other filings with the SEC. Any such forward-looking statements are based on current expectations, projections and estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.